Centro de Investigación de Medicina Aplicada (CIMA)
Centro / Instituto vinculado a la Universidad de Navarra
![Foto de Centro de Investigación de Medicina Aplicada (CIMA)](/img/uploaded/775F334D27340F135DFC5AC46D7B50CB.jpg)
![Foto de Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas](/img/noimage_org.png)
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (77)
2024
-
Development and characterization of a non-human primate model of disseminated synucleinopathy
Frontiers in Neuroanatomy, Vol. 18
2023
-
A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease
Parkinsonism and Related Disorders, Vol. 110
-
AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability
Brain, Behavior, and Immunity, Vol. 108, pp. 255-268
-
Boolean analysis shows a high proportion of dopamine D2 receptors interacting with adenosine A2A receptors in striatal medium spiny neurons of mouse and non-human primate models of Parkinson's disease
Neurobiology of Disease, Vol. 188
-
Engineering U1-Based Tetracycline-Inducible Riboswitches to Control Gene Expression in Mammals
ACS Nano, Vol. 17, Núm. 23, pp. 23331-23346
-
Loss of the matrix metalloproteinase-10 causes premature features of aging in satellite cells
Frontiers in Cell and Developmental Biology, Vol. 11
-
Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates
Brain : a journal of neurology, Vol. 146, Núm. 12, pp. 5000-5014
-
Preferential expression of SCN1A in GABAergic neurons improves survival and epileptic phenotype in a mouse model of Dravet syndrome
Journal of Molecular Medicine, Vol. 101, Núm. 12, pp. 1587-1601
2022
-
Adeno-Associated Viral Vectors as Versatile Tools for Neurological Disorders: Focus on Delivery Routes and Therapeutic Perspectives
Biomedicines, Vol. 10, Núm. 4
-
Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment
Life, Vol. 12, Núm. 11
-
Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria
Science Translational Medicine, Vol. 14, Núm. 627
2021
-
Adeno-associated viral vectors as versatile tools for parkinson’s research, both for disease modeling purposes and for therapeutic uses
International Journal of Molecular Sciences, Vol. 22, Núm. 12
-
An ACE2/Mas-related receptor MrgE axis in dopaminergic neuron mitochondria
Redox Biology, Vol. 46
-
Armcx3 mediates susceptibility to hepatic tumorigenesis promoted by dietary lipotoxicity
Cancers, Vol. 13, Núm. 5, pp. 1-22
-
Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration
Acta Neuropathologica Communications, Vol. 9, Núm. 1
-
Glucocerebrosidase gene therapy induces alpha-synuclein clearance and neuroprotection of midbrain dopaminergic neurons in mice and macaques
International Journal of Molecular Sciences, Vol. 22, Núm. 9
2020
-
Brain ventricular enlargement in human and murine acute intermittent porphyria
Human molecular genetics, Vol. 29, Núm. 19, pp. 3211-3223
-
Expression of GPR55 and either cannabinoid CB1 or CB2 heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates
Brain Structure and Function, Vol. 225, Núm. 7, pp. 2153-2164
-
Expression of cannabinoid CB1R–GPR55 heteromers in neuronal subtypes of the Macaca fascicularis striatum
Annals of the New York Academy of Sciences, Vol. 1475, Núm. 1, pp. 34-42
-
Neuroanatomical tract-tracing techniques that did go viral
Brain Structure and Function, Vol. 225, Núm. 4, pp. 1193-1224